Substance P

European Journal of Pain

Volumn 4, Issue 2, 2000, Pages 121-135

  Snijdelaar, Dirk G ^b   Dirksen, Ris ^a   Slappendel, Rob ^a   Crul, Ben J P ^c  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CALCITONIN GENE RELATED PEPTIDE; CALCIUM ION; CAPSAICIN; CYCLIC AMP; CYCLIC GMP; INOSITOL 1,4,5 TRISPHOSPHATE; LANEPITANT; LY 306740; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ B; NOLPITANTIUM; PHOSPHOLIPASE C; PROTEIN KINASE C; RP 100893; S 18523; SUBSTANCE P; UNCLASSIFIED DRUG; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE;

ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; DIABETIC NEUROPATHY; HERPES; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0034210444     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1053/eujp.2000.0171     Document Type: Review

References (162)

1. Abbadie C., Trafton J. A., Mantyh P. W., Basbaum A. I. Morphine does not reduce the enhancement of noxious stimulus-evoked internalization of the substance P receptor that occurs in spinal cord of rats with persistent hindpaw inflammation. Soc Neurosci Abstr. 22:1996;867.
2. Allen B. J., Li J., Simone D. A., Rogers S. D., Ghilardi J. R., Kotz C. M., Basbaum A. I., Mantyh P. W. Primary afferent sensory neurons that release substance P in the normal, transected, and inflamed rat. Soc Neurosci Abstr. 22:1996;1803.
3. Anand P. Nerve growth factor regulates nociception in human health and disease. Br J of Anaesth. 75:1995;201-208.
4. Anichini M., Ceseratti S., Lepori M., Maddali Bongi S., Maresca M., Zoppi M. Substance P in the serum of patients with rheumatoid arthritis. Rev Rhum Engl Ed. 64:1997;18-21.
5. Anton P. A., Shanahan F. Neuroimmunomodulation in inflammatory bowel disease. How far from `bench' to `bedside'? Ann N Y Acad Sci. 840:1998;723-734.
6. Appelgren A., Appelgren B., Kopp S., Lundeberg T., Theodorsson E. Substance P-associated increase of intra-articular temperature and pain threshold in the arthritic TMJ. J Orofac Pain. 12:1998;101-107.
7. Barclay R. K., Phillipps M. A. Inhibition of enkephalin-degrading aminopeptidase activity by certain peptides. Biochem Biophys Res Commun. 96:1980;1732-1738.
8. Beattie D. T., Beresford I. J. M., Connor H. E., Marshall F. H., Hawcock A. B., Hagan R. M., Bowers J., Birch P. J., Ward P. E. The pharmacology of GR 203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol. 116:1995;3149-3157.
9. 125I] Bolton Hunter derivatives of eledoisin and substance P in the rat brain. Neuroscience. 18:1986;857-875.
10. Biro T., Acs G., Acs P., Modarres S., Blumberg P. M. Recent advances in understanding of vanilloid receptors: a therapeutic target for treatment of pain and inflammation in the skin. J Invest Dermatol. 2:1997;56-60.
11. Blomqvist A., Mackerlova L. Spinal projections to the parabrachial nucleus are substance P-immunoreactive. Neuroreport. 6:1995;605-608.
12. Bonnet J., Kucharczyk N., Robineau P., Lonchampt M., Dacquet C., Regoli D., Faucherre J. L., Canet E. A water soluble, stable dipeptide NK1 receptor selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur J Pharmacol. 310:1996;37-46.
13. Bowker R. M., Westlund K. N., Sullivan M. C., Wilber J. F., Coulter D. Descending serotonergic, peptiderdic and cholinergic pathways from the raphe nuclei: a mutiple transmitter complex. Brain Res. 288:1983;33-48.
14. Brodin E., Linderoth B., Cazelius B., Ungerstedt U. In vivo release of substance P in cat dorsal horn studied with microdialysis. Neurosci Lett. 76:1987;357-362.
15. 3H]substance P in urinary bladders of cats with interstitial cystitis. J Urol. 160:1998;605-611.
16. Cao Y. Q., Mantyh P. W., Carlson E. J., Gillespie A. M., Epstein C. J., Basbaum A. I. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 392:1998;390-394.
17. Ch'ng J. L. C., Christofides N. D., Anand P., Gibson S. J., Allen Y. S., Su H. C., Tatemoto K., Morrison J. F., Polak J. M., Bloom S. R. Distribution of galanin immunoreactivity in the central nervous system and the response of galanin-containing neuronal pathways to injury. Neuroscience. 16:1985;343-354.
18. Chang M. M., Leeman S. E., Niall H. D. Amino-acid sequence of substance P. Nature. 232:1971;86-87.
19. Collins S. M. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology. 111:1996;1683-1699.
20. Cridland R. A., Henry J. L. Effects of intrathecal administration of neuropeptides on a spinal nociceptive reflex in the rat: VIP, galanin, CGRP, TRH, somatostatin and angiotensin II. Neuropeptides. 11:1988;23-32.
21. Csuhai E., Little S. S., Hersh L. B. Inactivation of neuropeptides. Nyberg F., Sharma H. S., Wiesenfeld-Hallin Z. Neuropeptides in the Spinal Cord. 1995;131-142 Elsevier Science B.V. Amsterdam.
22. Cuello A. C., Del Fiacco M., Paxinos G. The central and peripheral ends of substance P-containing sensory neurones in the rat trigeminal system. Brain Res. 152:1978;499-509.
23. Cuello A. C., Jessel T. M., Kanazawa I., Iversen L. L. Substance P localization in synaptic vesicles in rat central nervous system. J Neurochem. 29:1977;747-751.
24. Dalsgaard C. J., Haegerstrand A., Theodorsson E., Brodin E., Hokfelt T. Neurokinin-A like immunoreactivity in rat primary sensory neurons: co-existence with substance P. Histochemistry. 83:1985;37-40.
25. De Biasi S., Rustioni A. Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA. 85:1988;7820-7824.
26. De Felipe M. C., Herrero J. F., O'Brien J. A., Palmer J. A., Doyle C. A., Smith A. J. H., Laird J. M. A., Belmonte C., Cervero F., Hunt S. P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 392:1998;394-397.
27. Dirksen R. Opiaten en het endorfine systeem. I. Het endorfine systeem. Tijdschrift voor Geneesmiddelen Onderzoek. 2:1979a;401-411.
28. Dirksen R. Opiaten en het endorfine systeem. II. Opiaten. Tijdschrift voor Geneesmiddelen Onderzoek. 3:1979b;426-437.
29. Dirksen R. Opioid receptors and pain. Pharmaceutisch Weekblad. 12:1990;41-46.
30. Dirksen R. Analgesiology: a new approach to pain. Parris W. C.V. Contemporary issues in chronic pain management. 1991;33-49 Kluwer Academic Publishers, Massachusetts.
31. Dirksen R., Nijhuis G. G. M. Endorfines. Pijn en Pijnbestrijding IV. 1981;Exerpta Medica, Amsterdam. p. 3-65.
32. Dougherty P. M., Palecek J., Paleckova V., Sorkin L. S., Willis W. D. The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal and electrical stimuli. J Neurosci. 12:1992;3025-3041.
33. Dougherty P. M., Willis W. D. Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined micro-iontophoretic application of N-methyl-D-aspartic acid and substance P. Pain. 47:1991;85-93.
34. Duggan A. W. Neuropetide release in the spinal cord in response to noxious and non-noxious stimulation. Neuropeptides. 22:1992;19.
35. Duggan A. W., Hendry I. A., Morton C. R., Hutchison W. D., Zhao Z. Q. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res. 451:1988;261-273.
36. Duggan A. W., Morton C. R., Zhao Z. Q., Hendry I. A. Brain Res. 403:1987;345-349.
37. Edmonds Alt X., Doutremepuich J. D., Heaulme M., Neliat G., Santucci V., Steinberg R., Vilian P., Bichon D., Ducoux J. P., Proietto V., Van Broeck D., Soubrie P., Le Fur G., Breliere J. C. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol. 250:1993;403-413.
38. Eipper B. A., Stoffers D. A., Mains R. E. The biosynthesis of neuropeptides: peptide α -amidation. Annu Rev Neurosci. 15:1992;57-85.
39. Elliott T. R. On the action of adrenalin. J Physiol. 31:1904;20-21.
40. Erspamer V. The tachykinin peptide family. Trends Neurosci. 4:1981;267-269.
41. Fardin V., Carruette A., Menager J., Bock M., Flamand O., Foucault F., Heuillet E., Moussaoui S., Tabart M., Peyronel J. F., Garret C. In vitro pharmacological profile of RPR 100893, a novel non-peptide antagonist of the human NK1 receptor. Neuropeptides. 26:1994;34.
42. Folkers K., Feng D. M., Asano N., Hakanson R., Wiesenfeld Hallin Z., Leander S. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci USA. 87:1990;4833-4835.
43. Gaddum J. H., Schild H. Depressor substances in extracts of intestine. J Physiol (London). 83:1935;1-14.
44. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA. 88:1991;10208-10212.
45. Gilbert R. F., Emson P. C., Hunt S. P., Bennett G. J., Marsden C. D., Sandberg B. E., Steinbusch H. W., Verhofstad A. N. The effects of monoamine neurotoxins on peptides in the rat spinal cord. Neuroscience. 7:1982;69-87.
46. Go V. L. M., Yaksh T. L. Release of substance P from the cat spinal cord. J Physiol (London). 391:1987;141-167.
47. Gouarderes C., Jhamandas K., Cridland R., Cros J., Quirion R., Zajac J. M. Opioid and substance P receptor adaptations in the rat spinal cord following sub-chronic intrathecal treatment with morphine and naloxone. Neuroscience. 54:1993;799-807.
48. Hauser K., Heid J., Criscione L., Brugger F., Ofner S., Veenstra S., Schiling W. CGRP 49823, a novel, nonpeptidic NK1 receptor antagonist: In vitro pharmacology. Neuropeptides. 36:1994;37.
49. Heidenreich B. A., Nuseir K., Proudfit H. K. Antinociception produced by microinjecting substance P near the A7 catecholamine cell group may be reduced by structural changes in tyrosine hydroxylase immunoreactive dendrites. Soc Neurosci Abstr. 22:1996;868.
50. Henry J. L. Discussion of nomenclature for tachykinins and tachykinin receptors. Henry J. L., Couture R., Cuello A. C., Pelletier G., Quirion R., Regoli D. Substance P and Neurokinins. 1987;17-18 Springer-Verlag, New York.
51. Henry J. L. Substance P and inflammatory pain: potential of substance P antagonists as analgesics. Agents Actions Suppl. 41:1993;75-87.
52. Hirai T., Jones E. G. Distribution of tachykinin- and enkephalin-immunoreactive fibers in the human thalamus. Brain Res Rev. 14:1989;35-52.
53. Hirota N., Kuraishi Y., Hino Y., Sato Y., Satoh M., Takagi H. Met-enkephalin and morphine but not dynorphin inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn in situ. Neuropharmacology. 24:1985;567-570.
54. Hokfelt T., Kellerth J. O., Nilsson G., Pernow B. Substance P: localization in the central nervous system and in some primary sensory neurons. Science. 190:1975a;889-890.
55. Hokfelt T., Kellerth J. O., Nilsson G., Pernow B. Experimental immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurones. Brain Res. 100:1975b;235-252.
56. Hokfelt T., Ljungdahl A., Steinbusch H. W., Verhofstad A. N., Nilsson G., Brodin E., Pernow B., Goldstein M. Immunohistochemical evidence of substance P-like immunoreactivity in some 5- hydoxytryptamine-containing neurons in the rat central nervous system. Neuroscience. 3:1978;517-538.
57. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 43:1991;144-201.
58. Horn J. P. Integrative role of synaptic co-transmission in the bull-frog vasomotor C system: evidence for the synaptic gain hypothesis. J Physiol Pharmacol. 70:1992;s19-s20.
59. Hu H. Z., Li Z. W., Si J. Q. Evidence for the existence of substance P autoreceptor in the membrane of rat dorsal root ganglion neurons. Neuroscience. 77:1997;535-541.
60. Hylden J. L., Wilcox G. L. Intrathecal opioids block a spinal action of substance P in mice: functional importance of both m - and d - receptors. Eur J Pharmacol. 86:1983;95-98.
61. Jessel T. M., Iversen L. L. Opiate analgesics inhibit substance P release from the rat trigeminal nucleus. Nature. 268:1977;549-551.
62. Kage R., McGregor G. P., Thim L., Conlon J. M. Neuropeptide-g: a peptide isolated from rabbit intestine that is derived from g-preprotachykinin. J Neurochem. 50:1988;1412-1417.
63. Karlsten R., Gordh T. Jr. An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesh Analg. 80:1995;844-847.
64. Khawaja A. M., Rogers D. F. Tachykinins: receptor to effector. Int J Biochem Cell Biol. 28:1996;721-738.
65. Kimura S., Okada M., Sugita Y., Kanazawa I., Munekata E. Novel neuropeptides, neurokinin A and B, isolated from porcine spinal cord. Proc Jpn Acad. 59B:1983;101-104.
66. King A. E., Lopez-Garcia J. A. Excitatory amino acid receptor-mediated neurotransmission from cutaneous afferents in rat dorsal horn in vitro. J Physiol (London). 472:1993;443-457.
67. Klein C. M., Coggeshall R. E., Carlton S. M., Sorkin L. S. The effects of A- and C-fibre stimulation on patterns of neuropeptide immunostaining in the rat superficial dorsal horn. Brain Res. 580:1992;121-128.
68. Krause J. E., Chirgwin J. M., Carter M. S., Xu Z. S., Hershey A. D. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc Natl Acad Sci USA. 84:1987;881-885.
69. Krumins S. A., Kim D. C., Igwe O. J., Larson A. A. DAMGO binding to mouse brain membranes: influence of salts, guanine nucleotides, substance P, and substance P fragments. Peptides. 14:1993;309-314.
70. Kuraishi Y., Hirota N., Sato Y., Hino Y., Satoh M., Takagi H. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 325:1985;294-298.
71. Lantz I., Nyberg F., Terenius L. Molecular heterogenity of angiotensin converting enzyme in human cerebrospinal fluid. Biochem Int. 23:1991;941-948.
72. Lawson S. N. Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Nyberg F., Sharma H. S., Wiesenfeld-Hallin Z. Neuropeptides in the Spinal Cord. 1995;161-173 Elsevier, Amsterdam.
73. Le Greves P., Nyberg F., Terenius L., Hokfelt T. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol. 115:1985;309-311.
74. Leah J., Menetrey D., de-Pommery J. Neuropeptides in long ascending spinal tract cells in the rat: evidence for parallel processing of ascending information. Neuroscience. 24:1988;195-207.
75. Lee C. M., Iversen L. L., Hanley M. R., Sandberg B. E. The possible existence of multiple receptors for substance P. Naunyn Schmiedebergs Arch Pharmacol. 318:1982;281-287.
76. Lembeck F. Zur Frage der zentralen Ubertragung afferenter Impulse. III. Mitteilung. Das Vorkommen und die Bedeutung der Substanz P in den dorsalen Wurzeln des Ruckenmarks. Arch Exp Path Pharmakol. 219:1953;197-213.
77. Lewin G. R., Mendell L. M. Nerve growth factor and nociception. TINS. 16:1993;353-359.
78. Li J. L., Ding Y. Q., Shigemoto R., Mizuno N. Distribution of trigeminothalamic and spinothalamic tract neurons showing substance P receptor like immunoreactivity in the rat. Brain Res. 719:1996;207-212.
79. Light A. R., Perl E. R. Spinal termination of functionally identified primary afferent neurons with slowly conducting myelinated fibers. J Comp Neurol. 186:1979;133-150.
80. Liu H., Brown J. L., Jasmin L., Maggio J. E., Vigna S. R., Mantyh P. W., Basbaum A. I. Synaptic relationship between substance P and the substance P receptor: Light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci USA. 91:1994;1009-1013.
81. Liu H., Elde R., Basbaum A. I. Coexpression of mu opiod and substance P receptor-like immunoreactivity in a subpopulation of dorsal horn neurons in the rat. Soc Neurosci Abstr. 22:1996;2005.
82. Longmore J., Razzaque Z., Shaw D., Hill R. G. Differences in the effects of NK1-receptor antagonists CP-96,345 and CP-99,994 on agonist induced responses in guinea-pig trachea. Br J Pharmacol. 112:1994;176-178.
83. Luppi P. H., Sakai K., Fort P., Salvert D., Jouvet M. The nuclei of origin of monoaminergic, peptidergic, and cholinergic afferents to the cat nucleus reticularis magnocellularis: a double-labeling study with cholera toxin as a retrograde tracer. J Comp Neurol. 277:1988;1-20.
84. MacLeod A. M., Merchant K. J., Cascieri M. A., Sadowski S., Ber E., Swain C. J., Baker R. N-acyl-L-tryptophan benzyl esters: Potent substance P receptor antagonists. J Med Chem. 36:1993;2044-2045.
85. Maehara T., Suzuki H., Yoshioka K., Otsuka M. Substance P-evoked release of amino acid transmitters from the newborn rat spinal cord. Regul Pept. 46:1993;354-356.
86. Maggio J. E. Tachykinins. Annu Rev Neurosci. 11:1996;13-28.
87. Mantyh P. W., Mantyh C. R., Gates T., Vigna S. R., Maggio J. E. Receptor binding sites for substance P and substance K in the canine gastrointestinal tract and their possible role in inflammatory bowel disease. Neuroscience. 25:1988;817-837.
88. Marchand J. E., Sant G. R., Kream R. M. Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol. 81:1998;224-228.
89. Maszczynska I., Lipkowski A. W., Carr D., Kream R. M. Dual functional interactions of substance P and opioids in nociceptive transmission: review and reconciliation. Analgesia. 3:1998;259-268.
90. Matsamura H., Sakurada T., Hara H., Sakurada S., Kisara K. Characterization of the hyperalgesic effect induced by intrathecal injection of substance P. Neuropharmacology. 4:1985;421-426.
91. Matsas R., Kenny A. J., Turner A. J. The metabolism of neuropeptides: the hydrolysis of peptides including enkephalins, tachykinins and their analogues, by endopeptidase 24.11. Biochem J. 223:1984;433-440.
92. Matsas R., Kenny A. J., Turner A. J. An immunohistochemical study of endopeptidase-24.11 (enkephalinase) in the pig nervous system. Neuroscience. 18:1986;991-1012.
93. McCarson K. E., Krause J. E. The formalin-induced expression of tachykinin peptide and neurokinin receptor messenger RNAs in rat sensory ganglia and spinal cord is modulated by opiate preadministration. Neuroscience. 64:1995;729-739.
94. McLean S., Ganong A., Seymour P. A., Snider R. M., Desai M. C., Osen T., Bryce D. K., Longo K. P., Reynolds L. S., Robinson G., Schmidt A. W., Siok K., Heym J. Pharmacology of CP99994, a nonpeptide antagonist of the tachykinin NK1 receptor. J Pharmacol Exp Ther. 267:1993;472-479.
95. McLeod A. L., Karpitiskiy V. V., Krause J. E., Ribeiro da Silva A. Direct apposition of substance P and NK-1 receptor immunoreactivities in the rat spinal dorsal horn: an ultrastructural double-labelling study. Soc Neurosci Abstr. 22:1996;859.
96. Michaels L. A., Ohene-Frempong K., Zhao H., Douglas S. D. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood. 92:1998;3148-3151.
97. Mussap C. J., Geraghty D. P., Burcher E. Tachykinin receptors: a radioligand binding perspective. J Neurochem. 6:1993;1987-2009.
98. Nichols M. L., Allen B. J., Rogers S. D., Ghilardi J. R., Honore P., Luger N. M., Finke M. P., Li J., Lappi D. A., Simone D. A., Mantyh P. W. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science. 286:1999;1558-1561.
99. Nolano M., Simone D. A., Wendelschafer-Crabb G., Kennedy W. R. Decreased sensation and loss of epidermal nerve fibers following repeated topical application of capsaicin in humans. Soc Neurosci Abstr. 22:1996;1802.
100. Nowak J. M., Macdonald R. L. Substance P: ionic basis for depolarizing responses of mouse spinal cord neurons in cell culture. J Neurosci. 2:1982;1119-1128.
101. Nyberg F., Le Greves P., Sundqvist C., Terenius L. Characterization of substance P (1-7) en (1-8) generating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun. 125:1984;244-250.
102. Park K., Max M. B., Robinovitz E., Gracely R. H., Bennett G. J. Effects of intravenous ketamine, alfentanil or placebo on pain, pinprick hyperalgesie and allodynia produced by intradermal capsaicin in human subjects. Pain. 63:1995;163-172.
103. Parnham M. J., Dickenson A. H. Developments and clinical leads in nonopioid analgesics. Analgesia. 2:1996;43-56.
104. Patacchini R., Asolfi M., Quartara L., Rovero P., Giachetti A., Maggi C. A. Further evidence for the existence of NK2 tachykinin receptor subtypes. Br J Pharmacol. 104:1991;91-96.
105. Pernow B. Studies on substance P. Purification, occurrence and biological actions. Acta Physiol Scand. 29:1953;1-90.
106. Persson S., Le Greves P., Thornwall M., Eriksson U., Silberring J., Nyberg F. Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Nyberg F., Sharma H. S., Wiesenfeld-Hallin Z. Neuropeptides in the Spinal Cord. 1995;111-130 Elsevier Science B.V. Amsterdam.
107. Pickel V. M., Reis D. J., Leeman S. E. Ultrastructural localization of substance P in neurons of rat spinal cord. Brain Res. 122:1977;534-540.
108. Piercey M. F., Dobry P. J. K., Shroeder L. A., Einsphar F. J. Behavorial evidence that substance P may be a spinal cord sensory neurotransmitter. Brain Res. 210:1981;407-412.
109. Radhakrishnan V., Henry J. L. Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P. Neurosci Lett. 132:1991;39-43.
110. Radhakrishnan V., Henry J. L. Electrophysiology of neuropeptides in the sensory spinal cord. Nyberg F., Sharma H. S., Wiesenfeld-Hallin Z. Neuropeptides in the Spinal Cord. 1995;175-195 Elsevier Science B.V, Amsterdam.
111. Radhakrishnan V., Iyengar S., Henry J. L. The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli. Neuroscience. 84:1998;1251-1260.
112. Rains C., Bryson H. M. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging. 7:1995;317-328.
113. Randic M., Miletic V. Effect of substance P in cat dorsal horn neurones activated by noxious stimuli. Brain Res. 128:1977;164-169.
114. Ribeiro da Silva A., De Koninck Y., Cuello A. C., Henry J. L. Enkephalin-immunoreactive nociceptive neurons in the cat spinal cord. Molec Neurosci Neuroreport. 3:1992;25-28.
115. Ricciardi K. H., Blaustein J. D. Projections from ventrolateral hypothalamic neurons containing progestin receptor-and substance P-immunoreactivity to specific forebrain and midbrain areas in female guinea pigs. J Neuroendocrinol. 6:1994;135-144.
116. Routh V. H., Helke C. J. Tachykinin receptors in the spinal cord. Nyberg F., Sharma H. S., Wiesenfeld-Hallin Z. Neuropeptides in the Spinal Cord. 1995;93-108 Elsevier Science B.V. Amsterdam.
117. Ruda M. A. The pattern and place of nociceptive modulation in the dorsal horn. A discussion of the anatomically characterized neural circuitry of enkephalin, serotonin and substance P. Yaksh T. L. Spinal Afferent Processing. 1986;141-164 Plenum Press, New York.
118. Rupniak N. M., Boyce S., Williams A. R., Cook G., Longmore J., Seabrook G. R., Caeser M., Iversen S. D., Hill R. G. Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol. 110:1993;1607-1613.
119. Rusin K. I., Jiang M. C., Cerne R., Randic M. Interactions between excitatory amino acids and tachykinins in the rat spinal dorsal horn. Brain Res Bull. 30:1993;329-338.
120. Rusin K. I., Ryu P. D., Randic M. Modulation of excitatory amino acid responses in rat dorsal horn neurons by tachykinins. J Nuerphysiol. 68:1992;265-286.
121. Salter M. W., Henry J. L. Purine-induced depression of dorsal horn neurons in the cat spinal cord: enhancement by tachykinins. Neuroscience. 23:1987;903-915.
122. Salter M. W., Henry J. L. Tachykinins enhance the depression of spinal nociceptive neurons caused by cutaneously applied vibration in the cat. Neuroscience. 27:1988;243-249.
123. Santicioli P., Del Bianco E., Tramontana M., Maggi C. A. Adenosine inhibits action potential-dependent release of calcitonin gene-related peptide- and substance P-like immunoreactivities from primary afferents in rat spinal cord. Neuroscience Letters. 144:1992;211-214.
124. 2+channels. Eur J Pharmacol. 215:1992;351-352.
125. Schwarz M. J., Spath M., Muller-Bardorff H., Pongratz D. E., Bondy B., Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett. 259:1999;196-198.
126. 2+] mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol. 317:1996;129-135.
127. Segerdahl M., Ekblom A., Sandelin K., Wickman M., Sollevi A. Peroperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesthesia & Analgesia. 80:1995a;1145-1149.
128. Segerdahl M., Ekblom A., Sjolund K. F., Belfrage M., Forsberg C., Sollevi A. Systemic adenosine attenuates touch evoked allodynia induced by mustard oil in humans. Neuroreport. 6:1995b;753-756.
129. Sim L. J., Joseph S. A. Arcuate nucleus projections to brainstem regions which modulate nociception. J Chem Neuroanat. 4:1991;97-109.
130. Sim L. J., Joseph S. A. Serotonin and substance P afferents to paravascicular and central medial nuclei. Peptides. 13:1992;171-176.
131. Sjolund K. F., Sollevi A., Segerdahl M., Lundeberg T. Intrathecal adenosine analog administration reduces substance P in cerebrospinal fluid along with behavioral effects that suggest antinociception in rats. Anesth Analg. 85:1997;627-632.
132. Skidgel R. A., Engelbrecht S., Johnson A. R., Erdos E. G. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 5:1984;769-776.
133. Skilling S. R., Harkness D. H., Larson A. A. Experimental peripheral neuropathy decreases the dose of substance P required to increase excitatory amino acid release in the CSF of rat spinal cord. Neurosci Lett. 139:1992;92-96.
134. Snider R. M., Constantine J. W., Lowe J. A. 3d, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W., Hess H. J. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 251:1991;435-437.
135. Sprott H., Bradley L. A., Oh S. J., Wintersberger W., Alarcon G. S., Mussell H. G., Tseng A., Gay R. E., Gay S. Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum. 41:1998;1689-1694.
136. Starr M. S., James T. A., Gaytten D. Behavioural depressant and antinociceptive properties of substance P in the mouse; possible implication of brain monoamines. Eur J Pharmacol. 48:1978;203-212.
137. Stewart J. M., Getto C. J., Neldner K., Reeve E. B., Krivoy W. A., Zimmermann E. Substance P and analgesia. Nature. 262:1976;784-785.
138. Szallasi A., Blumberg P. M. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain. 68:1996;195-208.
139. Takahashi T., Otsuka M. Regional distribution of substance P in the spinal cord and nerve roots of the cat and the effect of dorsal root section. Brain Res. 87:1975;1-11.
140. 2agonist. Peptides. 14:1993;371-378.
141. Tatemoto K., Lundberg J. M., Jornvall H., Mutt V. Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin. Biochem Biophys Res Commun. 128:1985;947-953.
142. Tohyama M., Shiotani Y. Neuropeptides in spinal cord. Prog Brain Res. 66:1985;117-218.
143. Ueda M., Kuraishi Y., Sugimoto K., Satoh M. Evidence that glutamate is released from capsaicin-sensitive primary afferent fibers in rats: study with on-line continuous monitoring of glutamate. Neurosci Res. 20:1994;231-237.
144. Urban L., Randic M. Slow excitatory transmission in rat dorsal horn: possible mediation by peptides. Brain Res. 290:1984;336-341.
145. Urban L., Nagy J. Is there a nociceptive carousel? TiPS. 18:1998;223-224.
146. Vassout A., Schaub M., Gentsch C., Ofner S., Schiling W., Veenstra S. CGP 49823, a novel NK1 receptor antagonist: Behavioural effects. Neuropeptides. 26:1994;38.
147. Vilim F. S., Cropper E. C., Price D. A., Kupfermann I., Weiss K. R. Release of peptide cotransmitters in Aplysia: regulation and functional implications. J Neurosci. 15:1996;8105-8114.
148. Von Euler U. S., Gaddum J. H. An unidentified depressor substance in certain tissue extracts. J Physiol. 72:1931;74-87.
149. Wang X. M., Zhang K. M., Mokha S. S. Microinjection of substance P into the Kolloker Fuse nucleus inhibits or facilitates NMDA-evoked responses of neurons in the superficial and deeper dorsal horn of the medulla. Soc Neurosci Abstr. 22:1996;1360.
150. Wang Z. Y., Tung S. R., Strichartz G. R., Hakanson R. Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist. Br J Pharmacol. 111:1994;1342-1346.
151. Warden M. K., Young W. S. Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system. J Comp Neurol. 272:1988;90-113.
152. Watkins J. C. Structure-activity relationships in the development of excitatory amino acid receptors agonists and competitive antagonists. Trends Pharmacol Sci. 11:1990;25-33.
153. Weihe E. Neuropeptides in primary sensory neurons. Zenker W., Neuhuber W. The primary afferent neuron - A survey of recent morpho-functional aspects. 1990;127-159 Plenum, New York.
154. Wiesenfeld-Hallin Z., Hokfelt T., Lundberg J. M., Forssmann W. G., Reinecke M., Tschopp F. A., Fischer J. A. Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavorial responses of the rat. Neurosci Lett. 52:1984;199-204.
155. Wiesenfeld-Hallin Z., Xu X. J. The differential roles of substance P and neurokinin A in spinal cord hyperexcitability and neurogenic inflammation. Regul Pept. 46:1993;165-173.
156. Winter J., Bevan S., Campbell E. A. Capsaicin and pain mechanisms. Br J Anaesth. 75:1995;157-168.
157. Xu X. J., Wiesenfeld-Hallin Z., Villar M. J., Fahrenkrug J., Hokfelt T. On the role of galanin, substance P and other neuropeptides in primary sensory neurons of the rat: studies on spinal reflex excitability and peripheral axotomy. Eur J Neurosci. 2:1990;733-743.
158. Yaksh T. L., Jessel T. M., Gamse R., Mudge A. W., Leeman S. E. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature. 286:1980;455-457.
159. Yoshimura M., Jessel T. M. Amino acid-mediated EPSPs at primary afferent synapses with substantia gelatinosa neurones in the rat spinal cord. J Physiol (London). 430:1990;315-335.
160. Yoshimura M., Nishi S. Blind patch-clamp recordings from substantia gelatinosa in adult rat spinal cord slices: pharmacological properties of synaptic currents. Neuroscience. 53:1993;519-526.
161. Yu L. C., Hansson P., Lundeberg T. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawal responses in rats. Brain Res. 653:1994;223-230.
162. Zimmer A., Zimmer A. M., Baffi J., Usdin T., Reynolds K., Konig M., Palkovits M., Mezey E. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci USA. 95:1998;2630-2635.